Table 1. Comparison between the HO87... | American Society of Hematology

Table 1.

Comparison between the HO87 trial population and the gene-expression subset analyzed in this study

	Not in analysis (n = 456)		In analysis (n = 180)		Total (N = 636)		P
	n	%	n	%	N	%	P
Age, y							.22*
Median	73		72		73
Q1	69		69		69
Q3	77		76		77
Range	60-91		60-84		60-91
Sex							.43†
Male	253	55	93	52	346	54
Female	203	45	87	48	291	46
Treatment							.86†
MPT-T	226	50	91	51	317	50
MPR-R	230	50	89	49	319	50
ISS stage							.97†
I	116	26	44	25	160	25
II	217	48	87	49	304	48
III	118	26	46	26	164	26
FISH performed							<.001†
No	142	31	13	7	155	24
Yes	314	69	167	93	480	76
gain(1q)							.82†
No	143	64	82	62	225	63
Yes	81	36	50	38	131	37
del(13q)							.55†
No	160	58	85	54	245	56
Yes	118	42	72	46	190	44
del(17p)							.87†
No	256	90	136	89	392	90
Yes	28	10	16	11	44	10
t(4;14)							1.0†
No	280	92	146	91	426	91
Yes	26	8	14	9	40	9

	Not in analysis (n = 456)		In analysis (n = 180)		Total (N = 636)		P
	n	%	n	%	N	%	P
Age, y							.22*
Median	73		72		73
Q1	69		69		69
Q3	77		76		77
Range	60-91		60-84		60-91
Sex							.43†
Male	253	55	93	52	346	54
Female	203	45	87	48	291	46
Treatment							.86†
MPT-T	226	50	91	51	317	50
MPR-R	230	50	89	49	319	50
ISS stage							.97†
I	116	26	44	25	160	25
II	217	48	87	49	304	48
III	118	26	46	26	164	26
FISH performed							<.001†
No	142	31	13	7	155	24
Yes	314	69	167	93	480	76
gain(1q)							.82†
No	143	64	82	62	225	63
Yes	81	36	50	38	131	37
del(13q)							.55†
No	160	58	85	54	245	56
Yes	118	42	72	46	190	44
del(17p)							.87†
No	256	90	136	89	392	90
Yes	28	10	16	11	44	10
t(4;14)							1.0†
No	280	92	146	91	426	91
Yes	26	8	14	9	40	9

Genetic aberrations were not assessed for all patients, such that the numbers for these variables do not add to the mentioned totals.

Q1, quartile 1; Q3, quartile 3.

Kruskal-Wallis test.

Fisher’s exact test.